The meeting of the Advisory Committee on Vaccines (ACV).
The committee provided advice on the:
- extension of indication for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Spikevax; active ingredient Elasomeran; sponsor Moderna Australia Pty Ltd) that had been under evaluation from November 2021.
The committee provided advice on the following safety matter.
- Risk of Haemophagocytic lymphohistiocytosis (HLH) associated with Vaxzevria (formerly known as COVID-19 vaccine AstraZeneca)
Members
Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.
-
Meeting statementsAdvisory Committee on Vaccines, Meeting 31, 8 February 2022